Aims: Retinoic acid (RA) is used pharmacologically to treat neuroblastoma (NB), but its mechanism of action is unclear and it has limited use against refractory disease. This study investigated the expression of LSD1 (also known as KDM1A) in tumors, and assessed the efficacy of combining RA treatment with the inhibition of LSD1 expression. Methods: LSD1 protein expression levels were assessed semi-quantitatively in specimens of NB and ganglioneuroblastoma (GNB), along with the apoptosis markers, Bcl-2 and Bax. The combined effect of RA and LSD1 siRNA inhibition on cell death was then assessed in the human neuroblastoma cell line, SH-SY5Y. Results: LSD1 expression was higher in NB compared to GNB, and LSD1 overexpression directly correlated with Bcl-2 expression and inversely correlated with Bax expression. RA treatment or LSD1 siRNA inhibition alone inhibited the growth of SH-SY5Y cells, but did not cause significant apoptosis or cell death. Combined treatment led to higher rates of SH-SY5Y cell death, as reflected by an increased Bax/Bcl-2 ratio. Conclusions: The combined effect of RA and LSD1 siRNA inhibition had a synergistic effect on promoting the apoptosis of NB cells. This novel approach may improve the clinical treatment of NB.
Introduction
Neuroblastoma (NB) is the most predominant tumors occurring during early childhood. For example, it is the most common extracranial solid neoplasm in children, is responsible for 7% of malignancies in patients younger than 15 years, and represents ~15% of deaths due to childhood cancer [1] . NB has a favorable prognosis when diagnosed prenatally or in the newborn period; however, tumors that are diagnosed after the first year are often more 
Cellular Physiology and Biochemistry
Cell proliferation assay Cell proliferation was measured using a cell counting kit-8 (CCK-8, Dojindo Molecular Technologies, Japan), in accordance with the manufacturer's protocol. Briefly, the cell counting reagent was added to SH-SY5Y cells growing in 96-well plates, which were then incubated at 37°C for 2 h in a humidified 5% CO 2 atmosphere. Metabolically-active cells convert the water-soluble tetrazolium salt to a yellow-colored formazan dye product. The formazan dye is soluble in tissue culture medium and the quantity of formazan product, measured by absorbance at 450 nm, is directly proportional to the number of living cells in culture.
Apoptosis and Cell cycle analysis
To detect the changes of apoptosis, SH-SY5Y cells were were analyzed with Annexin V-EGFP/PI Apoptosis Detection Kit (R&S Biotech, Shanghai) according to the protocol of manufature. To monitor changes in the cell cycle distribution, cells were harvested 48 hr after treatment, washed with PBS, fixed in 70% ethanol and stained with 10 mg/ml propidium iodide.
LSD1 siRNA transfection
Cells were seeded in a six-well cell culture plate (2 x 10 5 cells/well) in 2 ml antibiotic-free normal growth medium supplemented with 10% FBS. The cells were incubated at 37°C in a CO 2 incubator until the cells were 60-80% confluent. This usually took 18-24 hours. Then, SH-SY5Y cells were transiently transfected with a small interfering RNA (siRNA) targeted against LSD1, or with a scrambled control siRNA (Santa Cruz Biotechnology, USA) according to the manufacturer's protocol.
Protein extraction and Western blot analysis
Western blotting was used to determine LSD1, PARP, Bcl-2 and Bax expression levels in extracts from SH-SY5Y cells grown in a 6-well plate. The cells were washed twice with cold PBS before adding radioimmunoprecipitation assay lysis buffer containing a protease inhibitor cocktail and a phosphatase inhibitor cocktail (Thermo Scientific). Extracts were centrifuged at 12,000 g for 15 mins at 4°C and the protein concentration was determined using a BCA protein assay (Thermo Scientific). Forty microgram-aliquots of extracted protein were run on SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were then incubated with primary antibodies, anti-full length PARP and anti-cleaved PARP from Abcam (USA), and others as indicated above, at 4°C overnight; the membranes were then incubated with secondary antibody coupled to horseradish peroxidase for 2 h. Immunoreactivity was visualized using enhanced chemiluminescence reagents (Thermo Scientific) and protein bands were quantified with a densitometer (Chemidoc MP; Bio Rad).
Statistical analysis
Statistical analysis was performed using SPSS Version 19.0 (SPSS; IBM, USA). The association between LSD1 expression and other variables was analyzed using the Spearman rank test. Other statistical analyses were carried out using the Student's t-test for unpaired data. A difference was considered significant if the p-value from a two-tailed test was less than 0.05.
Results

LSD1 is expressed in neuroblastoma and correlates significantly with Bcl-2 expression
In this study, we initially analyzed expression of LSD1 using a TMA containing 48 specimens, including 32 NBs and 16 GNBs. The clinical data for each specimen, as well as the score for LSD1, Bcl-2 and Bax expression is presented in Table 1 . Our data shows that LSD1 was expressed at a relatively higher level in NB compared to GNB (Fig. 1) . Similarly, Bcl-2 was also overexpressed in NB, and at relatively higher levels than in GNB (Fig. 1) . In contrast, the expression of Bax was much lower in NB and GNB (Fig. 1) . Correlations amongst LSD1, Bcl-2 and Bax expression were analyzed by the Spearman's rank test (Table 1 ). The results indicated that LSD1 expression positively correlated with the expression of Bcl-2 (LSD1 vs. Bcl-2: rho = 0.537; p = 0.001), and was inversely correlated with the expression of Bax (LSD1 vs. Bax; rho = 0.434, p = 0.03).
Combined effect of retinoic acid and LSD1 inhibition on SH-SY5Y cells
Taking into consideration that LSD1 was overexpressed in neuroblastic tumors, we further analyzed its functional relevance in NB. SH-SY5Y cells were transiently transfected with a small interfering RNA (siRNA) directed against LSD1, or with a scrambled control siRNA. A significant knockdown of LSD1 protein expression was detected 48 h after transfection (Fig. 4) . Upon siRNA-induced knockdown of LSD1, a decrease in cell viability Table 1 . Clinicopathological features and results of LSD1, Bcl-2 and Bax immunostaining in neuroblastic tumor samples. LSD1, Bcl-2, and Bax immunostaining were scored using a semi-quantitative method to evaluate the percentage of positive tumor cells (0-100%). Scores were categorized in 25% increments (-, negative; +, 25% positive; ++, 50%; +++, 75%; ++++, 100%). Protein expression was scored by three independent pathologists, who were blinded to the clinical data. A score was accepted if at least two of the pathologists were in agreement. (LSD1 vs. Bcl-2: rho = 0.537; p = 0.001) (LSD1 vs. Bax: rho = 0.434; p = 0.03).
was detected using cell proliferation assays (Fig. 2) . Decreased viability was accompanied by the appearance of morphologic features indicating differentiation or apoptosis, such as outgrowth of neurite-like structures and fragmentation of the nucleus. Moreover, flow cytometric analysis showed that apoptosis and subG1 fraction was increased significantly when treatment with LSD1-siRNA and RA (Fig. 3) .
To examine the possible effects of RA on growth and viability of SH-SY5Y cells, the cells were cultured with 10 μM RA and the numbers of viable cells were counted after 48 h. As shown in Fig. 2, 10 μM RA didn't significantly inhibited the proliferation of SH-SY5Y cells. To analyze the combined effect of LSD1 siRNA inhibition and RA on the death of SH-SY5Y cells, the cells were transfected with siRNA targeting LSD1 and exposed to 10 μM RA for 48 h. As shown in Fig. 2 , we observed an increase in cell death following the combined treatment. Furthermore, morphological changes in the form of neurite-like structures and fragmentation of the nucleus became more significant (Fig. 3) . Fig. 1 . LSD1, Bcl-2 and Bax expression in NB and GNB tissue microarrays. LSD1 expression was relatively higher in NB specimens (A, B) compared to GNB (C, D). Bcl-2 was also overexpressed in NB (E, F), and present at slightly lower levels in GNB (G, H). The expression of Bax was much lower in NB (I, J) and GNB (K, L).
Fig. 2.
The effect of RA and LSD1 inhibition alone or in combination on the growth of SH-SY5Y cells. SH-SY5Y cells were transfected with siRNA against LSD1 (10 μM) or RA treatment (10 μM) slightly inhibited the proliferation of SH-SY5Y cells. SH-SY5Y cells treated with combined RA and LSD1 siRNA inhibition showed a significant reduction in cell numbers after a 48 hr incubation.
Discussion
Present therapy for NB includes surgery, chemotherapy, radiation therapy and biological approaches [25] . RA has been shown to induce neuronal differentiation and/or apoptosis, and is widely used as a chemotherapeutic agent for treating patients with NB. Despite its efficacy, the effects of RA against refractory disease are limited. Moreover, resistance to RA represents a significant drawback to its clinical application. In this study, we demonstrated that LSD1 inhibition could enhance the ability of RA to promote the death of NB cells. LSD1, the first identified histone demethylase, is overexpressed in breast cancer, small cell lung cancer, colorectal, bladder and prostate cancers and neuroblastoma [19, 26, 27] .
We also found that LSD1 is strongly expressed in NB, and at much higher levels than in benign GNB. This result was consistent with reports that LSD1 expression was higher in undifferentiated neuroblastic tumors than in the differentiated tumors [27] . To further analyze the role of LSD1 in the pathogenesis of NB, we found that transient knockdown of LSD1 using siRNA increased the death of SH-SY5Y cells. Furthermore, we found that the effect of RA on the death of SH-SY5Y cells was significantly enhanced after LSD1 siRNA inhibition.
The pathogenesis of a wide variety of human diseases is frequently related to impaired control of apoptosis [28] . Indeed, we observed that Bcl-2 expression was high in neuroblastic tumors, but Bax expression was relatively low or undetectable. Moreover, expression of these proteins was correlated with LSD1 expression. This correlation suggested that the effect of RA and LSD1 inhibition on human SH-SY5Y cells may be mediated through the mitochondrial apoptotic pathway. Bcl-2 and Bax are important endogenous regulators of apoptosis and cellular activity in response to a variety of physiological and pathological insults [29, 30] . It is known that an increase in the Bax:Bcl-2 ratio can trigger the release of mitochondrial pro-apoptotic factors such as cytochrome C, Smac and AIF into the cytosol, which mediates apoptosis [29, 31] . Interestingly, Anna et al. indicated that overexpression of Bcl-2 after RAinduced differentiation of NB cells represented a loss of the apoptotic response or resistance 
